FGFR2 as a molecular target in endometrial cancer

Future Oncology

Volumn 5, Issue 1, 2009, Pages 27-32

  Byron, Sara A ^a   Pollock, Pamela M ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Endometrial cancer; FGFR2; Mutation; Therapeutic target; Tyrosine kinase

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTINEOPLASTIC AGENT; BIBF 1120; BRIVANIB; CEDIRANIB; FIBROBLAST GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHA 739358; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TKI 258; UNCLASSIFIED DRUG; FGFR2 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; ENDOMETRIUM CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MELANOMA; MICROSATELLITE INSTABILITY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; ENDOMETRIUM TUMOR; FEMALE; GENETICS; MUTATION; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MUTATION; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2;

EID: 65349087952     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.1.27     Document Type: Article

References (26)

1. Jereczek-Fossa B, Badzio A, Jassem J: Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J. Gynecol. Cancer 9, 285-294 (1999).
2. Creutzberg CL, van Putten WL, Koper PC et al.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355, 1404-1411 (2000)
3. Baselga J: Targeting tyrosine kinases in cancer the second wave. Science 312, 1175-1178 (2006).
4. Pollock PM, Gartside MG, Dejeza LC et al.: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158-7162 (2007).
5. Dutt A, Salvesen HB, Chen TH et al.: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA 105, 8713-8717 (2008).
6. Ornitz DM, Itoh N: Fibroblast growth factors. Genome Biol. 2(3), REVIEWS3005 (2001).
7. Mohammadi M, Olsen SK, Ibrahimi OA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107-137 (2005).
8. Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Hamel BC: FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am. J. Med. Genet. 112, 266-278 (2002).
9. Yu K, Herr AB, Waksman G, Ornitz DM: Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Natl. Acad. Sci. USA 97,14536-14541 (2000).
10. Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA: Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 251, 72-75 (1991).
11. Chen H, Ma J, Li W et al.: A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717-730 (2007).
12. Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24, 4783-4791 (2006).
13. Shiozawa T, Konishi I: Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int. J. Clin. Oncol. 11, 13-21 (2006).
14. Hamilton CA, Cheung MK, Osann K et al.: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared with grade 3 endometrioid corpus cancers. Br. J. Cancer 94, 642-646 (2006).
15. Byron SA, Gartside MG, Wellens CL et al.: Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation, Cancer Res. 68, 6902-6907 (2008).
16. Chen H, Isozaki K, Kinoshita K et al.: Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int. J. Cancer 105, 130-135 (2003).
17. Montiel-Duarte C, Cordeu L, Agirre X et al.: Resistance to imatinib mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk. Res. 32(5), 709-716 (2007).
18. Albitar L, Carter MB, Davies S, Leslie KK: Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecol. Oncol. 106, 94-104 (2007).
19. Nagata Y, Lan HK, Zhou X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
20. Lee SH, Lopes de Menezes D, Vora J et al.: In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res. 11, 3633-3641 (2005).
21. Sarker D, Molife R, Evans TR et al.: A Phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 14, 2075-2081 (2008).
22. Takeda M, Arao T, Yokote H et al.: AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 13, 3051-3057 (2007).
23. Rosen LS, Wilding G, Sweeney C et al.: Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 24(18S), 3051 (2006).
24. Carpinelli P, Ceruti R, Giorgini ML et al.: PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6, 3158-3168 (2007).
25. Carpinelli P, Moll J: Aurora kinases and their inhibitors: more than one target and one drug. Adv. Exp. Med. Biol. 610, 54-73 (2008).
26. Hilberg F, Roth GJ, Krssak M et al.: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782 (2008).